Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 15 to 23 amino acid residues in defined sequence
Reexamination Certificate
2006-03-06
2009-06-09
Lukton, David (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
15 to 23 amino acid residues in defined sequence
C530S325000, C530S327000, C530S328000, C530S329000
Reexamination Certificate
active
07544772
ABSTRACT:
The present invention includes methods of modulating cellular secretory processes. More specifically the present invention relates to modulating or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from the vesicles or granules in the inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. MANS peptide and active fragments thereof are useful in such methods.
REFERENCES:
patent: 4753945 (1988-06-01), Gilbard et al.
patent: 4873346 (1989-10-01), Anderson
patent: 5292498 (1994-03-01), Boucher
patent: 5298506 (1994-03-01), Stamler et al.
patent: 5436243 (1995-07-01), Sachs et al.
patent: 5849706 (1998-12-01), Molina y Vedia et al.
patent: 5849719 (1998-12-01), Carson et al.
patent: 5858784 (1999-01-01), Debs et al.
patent: 5858981 (1999-01-01), Schreiber et al.
patent: 5861502 (1999-01-01), Prockop et al.
patent: 6407058 (2002-06-01), Staddon et al.
patent: 6506779 (2003-01-01), Cheng et al.
patent: 2001/0033827 (2001-10-01), Kim
patent: 2003/0013652 (2003-01-01), Martin et al.
patent: 2004/0180836 (2004-09-01), Martin et al.
patent: 766800 (2003-10-01), None
patent: 0 551 200 (1993-07-01), None
patent: WO 93/00353 (1993-01-01), None
patent: WO 95/27496 (1995-10-01), None
patent: WO 96/18103 (1996-06-01), None
patent: WO 00/50062 (2000-08-01), None
patent: WO 01/20998 (2001-03-01), None
patent: WO 03/000027 (2003-01-01), None
patent: WO 2006/078899 (2006-07-01), None
patent: WO 2006/078899 (2006-12-01), None
Abdullah et al., “P2u purinoceptor regulation of mucin secretion in SPOC1 cells, a goblet cell line from the airways,” Biochem. J. vol. 316, 1996, pp. 943-951.
Abdullah et al., “Protein kinase C and Ca2+ activation of mucin secretion in airway goblet cells,” Am. Physiol. Soc. 273:L201-L210 (1997).
Aderem, “The MARCKS family of protein kinase-C substrates,” Biochem. Soc. Trans. 23:587-591 (1995).
Adler et al., “Effects of inflammatory mediators and drugs on mucus secretion and mucociliary function,” Res. Immunol. 149(3):245-248 (1998).
Adler et al., “Hypersecretion of Mucin in Response to inflammatory Mediators by Guinea Piog Tracheal Epithelial Cells In Vitro Is Blocked by Inhibition of Nitric Oxide Synthase,” Am. J. Respir. Cell Mol. Biol. 13:526-530 (1995).
Adler et al., “Myristoylated alanine-rich C-kinase substrate protein: A major intracellular regulatory molecule controlling secretion of mucin by human airway goblet cells,” Chest 117(5 suppl. 1):266S-267S (2000).
Aigner et al., “Depletion of 43-kD growth associated protein in primary sensory neurons leads to diminished formation and spreading of growth cones,” J. Cell Biol. 123(2):417-429 (1993).
Aragona et al., “Effects of a stable analogue pf PGE2 (11-deoxy-13, 14-didehydro-16 (S)-Methylester Methyl PGE2: FCE20700) on the secretory processes of conjunctival goblet cells of rabbit,” Exp. Eye Res. 45(5):647-654 (1987).
Barnes, P.J., “Current and future therapies for airway mucus hypersecretion,” Novartis Found Symp. 248:237-249 (2002).
Blackshear et al., “The MARCKS family of cellular protein kinase C substrates,” J. Biol. Chem. 268(3):1501-1504 (1993).
Bouffard et al., National Center for Biotechnology Information Database, Accession No. G20124. Sep. 28, 1998.
Calle et al., “Glucose-induced phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in isolated rat pancreatic islets,” J. Biol. Chem. 267(26):18723-18727 (1992).
Coffey et al., “Glutamate exocytosis and MARCKS phosphorylation are enhanced by a metabotopic glutamate receptor coupled to a protein kinase C synergistically activated by diacylglycerol and arachidonic acid,” J. Neurochem. 63(4):1303-1310 (1994).
Cross et al., “Antioxidant Protection: A Function of Tracheobronchial and Gastrointestinal Mucus,” The Lancet, Jun. 16, 1984, pp. 1328-1329.
Dizier et al., “Genome screen for asthma and related phenotypes in the French EGEA study,” American Journal Respiratory and Critical Care Medicine 162:1812-1818 (2000).
Dray-Charier et al., “Regulation of mucin secretion in human gallbladder epithelial cells: Predominant role of calcium and protein kinase C,” Gastroenterology 112(3):978-990 (1997).
Driot et al., “Beneficial effects of a retinoic acid analog, CBS-211 A, on an experimental model of keraoconjunctivitis Sicca.,” Invest. Opthalmol. Vis. Sci. 33(1):190-195 (1992).
Elzagallaai, A., et al. “Platelet Secretion Induced by Phorbol Esters Stimulation is Mediated Though Phosphorylation of MARCKS: a MARCKS-Derived Peptide Blocks MARCKS Phosphorylation and Serotonin Release without Affecting Pleckstrin Phosphorylation,” Hemostatis, Thrombosis, and Vascular Biology, 95(3):894-902. (Feb. 1, 2000).
European Search Report for application No. 02756467.3 dated Sep. 3, 2004.
Fischer et al., “Tumor Necrosis Factor-α Stimulates Mucin Secretion and Cyclic GMP Production by Guinea Pig Tracheal Epithelial Cells In Vitro,” Am. J. Respir. Cell Mol. Biol., vol. 20. 1999, pp. 413-422.
Garcher et al., “CA 19-9 ELISA test: A new method for studying mucus changes in tears,” Br. J. Ophthalmol. 82(1):88-90 (1998).
Gipson et al., “Cellular origin of mucins of the ocular surface tear film,” Adv. Exp. Med. Biol. 438:221-227 (1998).
Graff et al., “Protein Kinase C Substrate and Inhibitor Characteristics of Peptides Derived from the Myristoylated Alanine-rich C Kinase Substrate (MARCKS) Protein Phosphorylation Site Domain,” J. Biol. Chem. 266(22):14390-14398 (1991).
Harlan et al., “The human myristoylated alanine-rich C kinase substrate (MARCKS) gene (MACS),” J. Biol. Chem. 266(22):14399-14405 (1991).
Huse, “Partial European Search Report,” 4 pages, from European Patent application No. 04024019.4, European Patent Office, The Hague, The Netherlands (mailed May 3, 2005).
International Search Report corresponding to PCT/US02/22270 mailed on Jan. 22, 2003.
Kessler et al., “Stimulation of goblet cell mucous secretion by activation of nerves in rat conjunctiva,” Curr. Eye Res. 14(11):985-992 (1995).
Kim et al., “Airway goblet cell mucin: its structure and regulation of secretion,” Eur. Resp. J. 10(11):2644-2649 (1997).
Kim et al., “Airway Mucus,” Eur. Respir. J. vol. 10, 1997, p. 1438.
King et al., “Alteration of Airway Reactivity by Mucus, Respiration Physiology,” vol. 62, 1985, pp. 47-59.
Ko et al., “ATP-induced mucin release from cultured airway goblet cells involves, in part, activation of protein kinase C,” Am. J. Resp. Cell Mol. Biol. 16:194-198 (1997).
Ko et al., “ATP-induced Mucin Release from Cultured Airway Goblet Cells Involves, in Part, Activation of Protein Kinase C,” Am. J. Respir. Cell Mol. Biol. vol. 16, 1996, pp. 194-198.
Krunkosky et al., “Effects of TNFα on Expression of ICAM-1 in Human Airway Epithelial Cells In Vitro,” Am. J. Respir. Cell Mol. Biol., vol. 22, 2000, pp. 685-692.
Larivee et al., “Platelet-Activating Factor Induces Airway Mucin Release via Activation of Protein Kinase C: Evidence of Translocation of Protein Kinase C to Membranes,” Am. J. Respir. Cell Mol. Biol., vol. 11 , 1994, pp. 194-205.
Lethem et al., “Nucleotide Regulation of Goblet Cells in Human Airway Epithelial Explants: Normal Exocytosis in Cystic Fibrosis,” Am. J. Respir. Cell Mol. Biol., vol. 9, 1993, pp. 315-322.
Li, Y., et al., “MARCKS Protein is a Key Molecule Regulation Mucin Secretion by Human Airway Epithelial Cells in Vitro,” The Journal of Biological Chemistry. 276(44):40982-40990. (N
Adler Kenneth B.
Li Yuehua
Martin Linda D.
Parikh Indu
Takashi Shuji
Biomarck Pharmaceuticals, Ltd.
Cooley Godward Kronish LLP
Lukton David
LandOfFree
Methods for regulating inflammatory mediators and peptides... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for regulating inflammatory mediators and peptides..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for regulating inflammatory mediators and peptides... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4084050